{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:34:56Z","timestamp":1773041696724,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11916-018-0716-2","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T08:45:00Z","timestamp":1531730700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Emerging Treatments in Episodic Migraine"],"prefix":"10.1007","volume":"22","author":[{"given":"Kate W.","family":"Grimsrud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi B.","family":"Halker Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"issue":"11","key":"716_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBD 2015 Neurological Disorders Collaborator Group","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877\u201397. https:\/\/doi.org\/10.1016\/S1474-4422(17)30299-5 .","journal-title":"Lancet Neurol"},{"key":"716_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","unstructured":"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743\u2013800. https:\/\/doi.org\/10.1016\/S0140-6736(15)60692-4 .","journal-title":"Lancet"},{"key":"716_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337\u201345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"716_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/head.13081","volume":"57","author":"L Edvinsson","year":"2017","unstructured":"Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47\u201355. https:\/\/doi.org\/10.1111\/head.13081.","journal-title":"Headache"},{"issue":"27","key":"716_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233.","volume":"19","author":"AR Tso","year":"2017","unstructured":"Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(27):887\u201398. https:\/\/doi.org\/10.1177\/0333102416653233.","journal-title":"Curr Treat Options Neurol"},{"key":"716_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887\u201398. https:\/\/doi.org\/10.1177\/0333102416653233 .","journal-title":"Cephalalgia"},{"issue":"1","key":"716_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients\u2014a review of pros and cons. J Headache Pain. 2017;18(1):96. https:\/\/doi.org\/10.1186\/s10194-017-0807-1.","journal-title":"J Headache Pain"},{"key":"716_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clineuro.2017.01.009","volume":"154","author":"P Hong","year":"2017","unstructured":"Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg. 2017;154:74\u20138. https:\/\/doi.org\/10.1016\/j.clineuro.2017.01.009 .","journal-title":"Clin Neurol Neurosurg"},{"key":"716_CR9","doi-asserted-by":"publisher","first-page":"333102418759786","DOI":"10.1177\/0333102418759786","volume":"1","author":"DW Dodick","year":"2018","unstructured":"\u2022\u2022 Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;1:333102418759786. https:\/\/doi.org\/10.1177\/0333102418759786 . Recently published phase III trial examining CGRP receptor antibody erenumab.","journal-title":"Cephalalgia"},{"issue":"2","key":"716_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","volume":"75","author":"V Skljarevski","year":"2018","unstructured":"\u2022 Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187\u201393. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3859 . Recently published phase IIb trial examining CGRP antibody galcanezumab.","journal-title":"JAMA Neurol"},{"issue":"22","key":"716_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"\u2022\u2022 Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038 . Recently published phase III trial examining CGRP antibody fremanezumab.","journal-title":"N Engl J Med"},{"key":"716_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/WNL.26.1.41","volume":"26","author":"BW Somerville","year":"1976","unstructured":"Somerville BW. Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology. 1976;26:41\u20135.","journal-title":"Neurology"},{"key":"716_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltr\u00e1n","year":"2018","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Villal\u00f3n CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88\u201397. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.005 .","journal-title":"Pharmacol Ther"},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/JPR.S132833","volume":"11","author":"A Negro","year":"2018","unstructured":"Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515\u201326. https:\/\/doi.org\/10.2147\/JPR.S132833 .","journal-title":"J Pain Res"},{"key":"716_CR15","unstructured":"Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). 2017. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT02605174?term=lasmiditan&rank=1 . https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=1036101"},{"key":"716_CR16","unstructured":"An open-label, long-term, safety study of lasmiditan for the acute treatment of migraine (GLADIATOR). 2017. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02565186?term=GLADIATOR&rank=3 ."},{"key":"716_CR17","doi-asserted-by":"publisher","unstructured":"Sundrum T, Walker CS. PACAP receptors in the trigeminovascular system: implications for migraine. Br J Pharmacol. 2017; https:\/\/doi.org\/10.1111\/bph.14053.","DOI":"10.1111\/bph.14053."},{"issue":"1","key":"716_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","volume":"19","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Tatji J, Szalardy L, Vecsei L. PACAP and its role in primary headaches. J Headache Pain. 2018;19(1):21. https:\/\/doi.org\/10.1186\/s10194-018-0852-4 .","journal-title":"J Headache Pain"},{"issue":"1","key":"716_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-018-0850-6","volume":"19","author":"JA Waschek","year":"2018","unstructured":"Waschek JA, Baca SM, Akerman S. PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain. 2018;19(1):23. https:\/\/doi.org\/10.1186\/s10194-018-0850-6 .","journal-title":"J Headache Pain"},{"issue":"308","key":"716_CR20","doi-asserted-by":"publisher","first-page":"308ra157","DOI":"10.1126\/scitranslmed.aaa7557","volume":"7","author":"S Akerman","year":"2015","unstructured":"Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015;7(308):308ra157. https:\/\/doi.org\/10.1126\/scitranslmed.aaa7557 .","journal-title":"Sci Transl Med"},{"issue":"4","key":"716_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/head.13069","volume":"57","author":"F Puledda","year":"2017","unstructured":"Puledda F, Goadsby PJ. An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache. 2017;57(4):685\u201391. https:\/\/doi.org\/10.1111\/head.13069 .","journal-title":"Headache"},{"issue":"4","key":"716_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(10)70054-5","volume":"9","author":"RB Lipton","year":"2010","unstructured":"Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(10)70054-5 .","journal-title":"Lancet Neurol"},{"key":"716_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s10194-015-0535-3","volume":"16","author":"R Bhola","year":"2015","unstructured":"Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535. https:\/\/doi.org\/10.1186\/s10194-015-0535-3.","journal-title":"J Headache Pain"},{"key":"716_CR24","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/0333102418762525","volume":"1","author":"AJ Starling","year":"2018","unstructured":"Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018;1: 333102418762525:1038\u201348. https:\/\/doi.org\/10.1177\/0333102418762525 .","journal-title":"Cephalalgia"},{"key":"716_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40122-015-0039-5","volume":"4","author":"F Riederer","year":"2015","unstructured":"Riederer F, Penning S, Schoenen J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly device for migraine prevention: a review of the available data. Pain Ther. 2015;4:135\u201347. https:\/\/doi.org\/10.1007\/s40122-015-0039-5 .","journal-title":"Pain Ther"},{"issue":"9","key":"716_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1177\/0333102416656118","volume":"37","author":"D Magis","year":"2017","unstructured":"Magis D, D\u2019Ostilio K, Thibaut A, de Pasqua V, Gerard P, Hustinx R, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2017;37(9):881\u201391. https:\/\/doi.org\/10.1177\/0333102416656118 .","journal-title":"Cephalalgia"},{"key":"716_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","volume":"80","author":"J Schoenen","year":"2013","unstructured":"Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697\u2013704. https:\/\/doi.org\/10.1212\/WNL.0b013e3182825055 .","journal-title":"Neurology"},{"key":"716_CR28","doi-asserted-by":"publisher","unstructured":"Magis D, Sava S, d\u2019Elia TS, Baschi R, Schoenen J. Safety and patients\u2019 satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14(95) https:\/\/doi.org\/10.1186\/1129-2377-14-95.","DOI":"10.1186\/1129-2377-14-95."},{"key":"716_CR29","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1212\/WNL.0000000000003760","volume":"88","author":"D Yarnitsky","year":"2017","unstructured":"Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88:1250\u20135. https:\/\/doi.org\/10.1212\/WNL.0000000000003760 .","journal-title":"Neurology"},{"issue":"5","key":"716_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.pain.2014.02.009","volume":"155","author":"ML Oshinsky","year":"2014","unstructured":"Oshinsky ML, Murphy AL, Hekierski H Jr, Cooper M, Simon BJ. Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain. 2014;155(5):1037\u201342. https:\/\/doi.org\/10.1016\/j.pain.2014.02.009 .","journal-title":"Pain"},{"issue":"4","key":"716_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/j.pain.0000000000000437","volume":"157","author":"SP Chen","year":"2016","unstructured":"Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016;157(4):797\u2013805. https:\/\/doi.org\/10.1097\/j.pain.0000000000000437 .","journal-title":"Pain"},{"issue":"12","key":"716_CR32","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1177\/0333102414524494","volume":"34","author":"PJ Goadsby","year":"2014","unstructured":"Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986\u201393. https:\/\/doi.org\/10.1177\/0333102414524494 .","journal-title":"Cephalalgia"},{"key":"716_CR33","doi-asserted-by":"crossref","unstructured":"Tassorelli C, Grazzi L, De Tommaso M, et al. The PRESTO Trial. Neurology 2018; 90 (15 Supplement).","DOI":"10.1212\/WNL.90.15_supplement.S43.005"},{"issue":"13","key":"716_CR34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/0333102416678623","volume":"37","author":"Y Juan","year":"2017","unstructured":"Juan Y, Shu O, Jinhe L, Na Y, Yushuang D, Weiwei D, et al. Migraine prevention with percutaneous mastoid electrical stimulator: a randomized double-blind controlled trial. Cephalalgia. 2017;37(13):1248\u201356. https:\/\/doi.org\/10.1177\/0333102416678623 .","journal-title":"Cephalalgia"},{"key":"716_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/head.13120","volume":"57","author":"D Wilkinson","year":"2017","unstructured":"Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, et al. Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial. Headache. 2017;57:1065\u201387. https:\/\/doi.org\/10.1111\/head.13120 .","journal-title":"Headache"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-018-0716-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-018-0716-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-018-0716-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:06:47Z","timestamp":1720426007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-018-0716-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1007\/s11916-018-0716-2","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"16 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kate W. Grimsrud declares no conflict of interest. Rashmi B. Halker Singh has received consulting fees from Amgen and Allergan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"61"}}